Receptor News and Research

RSS

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Researchers in China have demonstrated interferon-alpha (IFN-α) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-α priming was shown to promote lipid uptake and foam cell formation—a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE.

27 Jan 2011

How estrogen decreases risk and delays onset and progression of Alzheimer's disease

An influential article in the journal Progress in Neurobiology provided one of the first comprehensive reviews of how estrogen potentially can protect against Alzheimer's disease and other neurological disorders.

27 Jan 2011

Triggering CD45 molecule blocks early development of AD

A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer's disease (AD) has been discovered by researchers at the University of South Florida's Department of Psychiatry and the Center of Excellence for Aging and Brain Repair.

27 Jan 2011

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

26 Jan 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Researchers map complex choreography used by immune system's T cells to recognize pathogens

Researchers have for the first time mapped the complex choreography used by the immune system's T cells to recognize pathogens while avoiding attacks on the body's own cells.

21 Jan 2011

Vasopressin in the brain maintains size of vasopressin neurons even when body fluid becomes more diluted

The anti-diuretic hormone "vasopressin" is released from the brain, and known to work in the kidney, suppressing the diuresis.

21 Jan 2011

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors.

21 Jan 2011

Scientist receives RO1 research grant to improve blood, marrow transplantation in myeloma patients

Thea Friedman, M.D., associate scientist and director of oncology basic research at the John Theurer Cancer Center at Hackensack University Medical Center was recently awarded a National Cancer Institutes of Health-National Cancer Institute RO1 research grant to improve allogeneic blood and marrow transplantation for multiple myeloma patients.

21 Jan 2011

Researchers examine brain's role in breathing

Much of our knowledge of the brain's role in regulating breathing comes from research with mice and rats. A chemical receptor within the brain stem communicates with the central nervous system to generate the basic pattern of breathing. The next step is applying that information to human tissue to identify these critical components in the human brain and their medical implications.

21 Jan 2011

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.

20 Jan 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Receptor News and Research

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

How estrogen decreases risk and delays onset and progression of Alzheimer's disease

Triggering CD45 molecule blocks early development of AD

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

Eisai to seek marketing authorization for perampanel in the U.S. and EU

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Researchers map complex choreography used by immune system's T cells to recognize pathogens

Vasopressin in the brain maintains size of vasopressin neurons even when body fluid becomes more diluted

MedImmune announces MEDI-573 preclinical results against many solid tumors

Scientist receives RO1 research grant to improve blood, marrow transplantation in myeloma patients

Researchers examine brain's role in breathing

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Salk Institute uncovers presenilin's productive side

National Jewish Health issued method patent for desensitizing B cells

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News